-
TME Pharma reports on end of six-month lock-up period of shares and convertible bonds following the April 2023 transaction
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the end of the six-month soft lock-up period of shares and the end of the lock-up of convertible bonds following the transaction announced on April 18, 2023. As part of the April financing, 2,880,085 shares were issued and placed under a six-month soft lock-up. TME Pharma has been informed that during this period 2,305,000 shares were placed on the market at an average price of €1.43, i.e., 80% of the total of the issued shares. In parallel none of the 2,348 currently outstanding convertible…
-
Results of the 2023 Annual General Meeting of shareholders and resumption of the liquidity contract
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the results of its 2023 annual general meeting of shareholders (AGM), which took place on June 29, 2023, at 01:30 p.m. CEST. Shareholders representing a total of 39.86% of the total issued and outstanding share capital on June 01, 2023, were represented in person or by proxy. All proposed resolutions submitted to the AGM were approved, as outlined below. Following the approval of agenda item 7, and effective as of July 03, 2023, the company reinstates the liquidity contract with Invest Securities that was…
-
TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month mark further surpasses the expected survival in patients resistant to chemotherapy with incomplete surgical tumor removal Survival data will improve further as time progresses and patients remain on study Continued strong performance improves NOX-A12 profile for partnering and eligibility for accelerated regulatory pathways TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces a positive clinical update on the survival of first-line glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination…
-
TME Pharma Announces Convocation of the 2023 Annual General Meeting of Shareholders
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 01.30 p.m. CEST on June 29, 2023, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands. The annual accounts for the year ending December 31, 2022, and the report of the board of directors for 2022, the convocation to the AGM, the agenda and the explanatory notes to the agenda, the instructions and documents for participation and voting at the AGM are…
-
TME Pharma publishes audited annual report 2022
Financial visibility extended into December 2023 Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumab Survival data continue to improve with 83% of patients alive after one year 15-month survival data expected in mid-2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today its financial results for the fiscal year ending December 31, 2022. The Annual Report 2022, as approved by the management and supervisory boards on April 20, 2023, is available on TME Pharma’s website (www.tmepharma.com). "At TME Pharma we are…
-
TME Pharma Announces Successful €2 Million Financing and the End of the Convertible Bond Program with a Lock-Up of New Shares and Lock-Up of Bond Conversions Extending Financial Runway into December 2023
€2 million new cash secured Termination of the convertible bond agreement by TME Pharma Lock-up of all new shares issued and all outstanding convertible bonds for a period of 6 months to align investors and support company through next clinical results TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the successful closing of a financing of €2 million. The financing extends the company’s cash runway into December 2023, sufficient to reach its next major inflection points and to allow further advance its ongoing GLORIA Phase 1/2 clinical study of NOX-A12 combination…
-
TME Pharma Publishes Unaudited Financial Results for Fiscal Year 2022
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the publication of unaudited financial results for the fiscal year 2022 in order to allow the company to complete a transaction before publication of the annual report 2022. The audited annual report 2022 with the detailed financial statements will be published by end of April 2023 as in prior years. 2022 Financial Summary TME Pharma successfully strengthened its balance sheet by raising €7.3 million net cash under the Atlas Special Opportunities (ASO) facility in 2022. Considering cash and cash equivalents of €4.6 million as…
-
TME Pharma announces convocation of an extraordinary general meeting of shareholders
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an extraordinary general meeting of shareholders (the EGM) of the company is convened at 01.30 p.m. CET on January 30, 2023, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands. This EGM is convened to vote on the proposal to reduce the nominal value per share and increase authorized share capital. The EGM documentation, i.e., the convocation, the agenda and the explanatory notes to the agenda items 2 and 3, the instructions and documents for…
-
TME Pharma announces the resignation of its chief financial officer Bryan Jennings
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the company’s Chief Financial Officer (CFO), Bryan Jennings, has resigned for personal reasons. He will remain in his role through December 31, 2022, in order to ensure a smooth transition period. To preserve financial resources, ongoing financing and partnering activities will be pursued by CEO Aram Mangasarian, long-standing members of staff Senior Vice President of Finance, Heike Balzer, and Vice President Legal and General Counsel, Karen Ophoff, as well as newly appointed Senior Director Investor Relations and Business Development, Ewelina Staniuk.…
-
TME Pharma reports H1 2022 Financial results and provides business update
Promising top-line results warrant focus of the clinical development on NOX-A12 combination therapies in brain cancer NOX-A12 + bevacizumab 12-month survival data in glioblastoma expected in April 2023 Cash runway into June 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces its financial results and business highlights for the six months ending June 30, 2022, and provides an outlook for the rest of the year. Aram Mangasarian, CEO of TME Pharma commented: "In the last several months, years of focused efforts and commitment to our mission to develop novel therapies for cancer…
